BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 31, 2011
 |  BioCentury  |  Product Development

Safety in psoriasis

ChemoCentryx hopes CCX832 safer than biologics, older systemics in psoriasis

Psoriasis has become a crowded space, with more than 60 products in Phase II and beyond. ChemoCentryx Inc. hopes its CCX832 will be more effective than topicals that are good only for mild psoriasis, without the toxicities and risks of infection that accompany standard of care for moderate to severe disease. The company believes the compound is the first ChemR23 inhibitor to enter human studies, with a Phase I trial that began last week.

Older systemic therapies to treat chronic, moderate to severe psoriasis come with risks. For example, methotrexate can cause hematotoxicity and hepatotoxicity, and cyclosporine can cause nephrotoxicity.

Biologics for the indication also come with risks. For example, at least six approved biologics have warnings for serious infections and malignancies because they inhibit targets that are essential...

Read the full 637 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >